Marshall Wace, LLP Passage Bio, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.86 - $1.73 $18,911 - $38,042	21,990 New	21,990 $29,000
Q3 2022 Nov 14, 2022	BUY	$1.22 - $2.48 $10,413 - $21,169	8,536 Added 4.61%	193,650 $242,000
Q2 2022 Aug 15, 2022	SELL	$1.63 - $3.46 $22,456 - $47,668	-13,777 Reduced 6.93%	185,114 $438,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.49 $460,039 - $1.12 Million	172,947 Added 666.62%	198,891 $616,000
Q4 2021 Feb 14, 2022	SELL	$6.24 - $10.2 $280,668 - $458,785	-44,979 Reduced 63.42%	25,944 $165,000
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $1.19 Million - $1.89 Million	-121,988 Reduced 63.24%	70,923 $705,000
Q2 2021 Aug 13, 2021	SELL	$12.44 - $19.45 $1.53 Million - $2.39 Million	-122,959 Reduced 38.93%	192,911 $2.56 Million
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $5.13 Million - $9.42 Million	315,870 New	315,870 $5.52 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.